T.N. BEBNEVA^1,2, G.B. DIKKE³

 ¹Russian University of Peoples Friendship of the Ministry of Education and Science, Moscow

²National Medical Research Center of Endocrinology of the Ministry of Health of Russia, Moscow

³Academy of Medical Education named after F.I. Inozemtsev, Saint Petersburg

Contact details:

Bebneva T.N. — PhD (medicine), Associate Professor of the Department of Obstetrics, Gynecology and Reproductive Medicine

Address: 21 Miklukho-Maklay St., building 3, Russian Federation, Moscow, 117198, tel.: +7-916-518-19-64, e-mail: [email protected]

The purpose — to determine the expression of Ki-67 and p16 in pregnant women infected with HPV, and their role in the diagnosis and prognosis of severe cervical neoplasia.

Material and methods. Design: open-label observational non-interventional cohort clinical study. We examined 26 pregnant women infected with HPV, aged 23 to 31 years. Methods: general clinical nethods, Kvant-21 test for determining HPV types and quantitative load, cytological examination, determination of the expression of Ki-67 and p16 proteins by immunocytochemical method.

Results. It was shown that with an increase of the cervical lesion severity, the proportion of patients with tumor markers increased (from 20% with NILM to 100% with HSIL), and the intensity of Ki-67/p16 expression was moderate (2+) in 25% of patients with LSIL and high (3+) in 100% of patients with HSIL. A higher statistically significant viral load was detected for the HPV A9 DNA group (16, 31, 33, 35, 52, 58 types) upon detection of tumor markers compared with their absence, confirmed by a logit regression model with a sensitivity of 100% and a specificity of 89%.

Conclusion. Due to the lack of an unambiguous opinion about the extent to which changes in the expression of Ki-67 and p16 reflect information about the CIN evolution during pregnancy, further research is needed to obtain data that would allow for an appropriate interpretation of the revealed phenomena.

Key words: pregnancy, human papillomavirus, cervical diseases, Ki-67 and p16.

REFERENCES

1. Niyibizi J., Zanré N., Mayrand M.-H., Trottier H. The association between adverse pregnancy outcomes and maternal human papillomavirus infection: A systematic review protocol. Systematic Reviews, 2017, vol. 6 (1), p. 56. DOI: 10.1186/s13643-017-0443-5
2. Al-Halal H., Kezouh A., Abenhaim H. Incidence and obstetrical outcomes of cervical intraepithelial neoplasia and cervical cancer in pregnancy: A population-based study on 8.8 million births. Arch Gynecol Obstet, 2012, vol. 287 (2). DOI: 2.10.1007/s00404-012-2475-3
3. Beharee N., Shi Z., Wu D., Wang J. Diagnosis and treatment of cervical cancer in pregnant women. Cancer Med, 2019, vol. 8 (12), pp. 5425–5430. DOI: 10.1002/cam4.2435
4. Mailath-Pokorny M., Schwameis R., Grimm C., Reinthaller A., Polterauer S. Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature. BMC Pregnancy Childbirth, 2016, vol. 16, p. 74. DOI: 10.1186/s12884-016-0861-8
5. Shiping Z., Lushan Z.Q. et al. Progress in diagnosis and treatment of pregnancy complicated with cervical cancer. J Pract Med, 2018, vol. 25 (4), pp. 400–402.
6. Hellman K., Lindquist D., Ranhem C., Wilander E., Andersson S. Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagin. Br J Cancer, 2014, vol. 110 (6), pp. 1561–1570. DOI: 6. 10.1038/bjc.2014.32
7. Xi L.F., Hughes J.P., Castle P.E. et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis, 2011, vol. 203 (10), pp. 1425–1433. DOI:10.1093/infdis/jir049
8. Korolenkova L.I., Bryuzgin V.V. Severe cervical intraepithelial neoplasias (CIN 2-3 / pre-invasive cancer) and cervical microcarcinoma in pregnant women. Akusherstvo i ginekologiya, 2011, no. 5, pp. 68–74 (in Russ.).
9. Marks M., Gravitt P.E., Utaipat U. et al. Kinetics of DNA load predict HPV 16 viral clearance. J ClinVirol, 2011, vol. 51 (1), pp. 44–49. DOI: 10.1016/j.jcv.2011.01.011
10. Calil L.N., Edelweiss M.I., Meurer L. et al. p16 INK4a and Ki67 expression in normal, dysplastic and neoplastic uterine cervical epithelium and human papillomavirus (HPV) infection. Pathol. Res. Pract, 2014, vol. 210, pp. 482–487.
11. Tornesello M.L., Buonaguro L., Rossi G.P., Buonaguro F.M. Viral and cellular biomarkers in the diagnosis of cervical Intraepithelial neoplasia and cancer. Biomed. Res. Int, 2013, 519619. DOI: 10.1155/2013/519619
12. Chen C.C., Huang L.W., Bai C.H., Lee C.C. Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis. Ann Saudi Med, 2016, vol. 36 (4), pp. 245–251. DOI: 10.5144/0256-4947.2016.245
13. Castillo M., Astudillo A., Clavero O., Velasco J., Ibáñez R., de Sanjosé S. Poor Cervical Cancer Screening Attendance and False Negatives. A Call for Organized Screening. PLoS One, 2016, vol. 11 (8), p. e0161403. DOI: 10.1371/journal.pone.0161403
14. Nishio H., Iwata T., Nomura H., Morisada T., Takeshima N., Takano H., Sasaki H., Nakatani E., Teramukai S., Aoki D. Liquid-based cytology versus conventional cytology for detection of uterine cervical lesions: a prospective observational study. Jpn J Clin Oncol, 2018, vol. 48 (6), pp. 522–528. DOI: 10.1093/jjco/hyy050
15. Ciavattini A., Sopracordevole F., Di Giuseppe J. et al. Cervical intraepithelial neoplasia in pregnancy: Interference of pregnancy status with p16 and Ki-67 protein expression. Oncol. Lett, 2017, vol. 13 (1), pp. 301–306. DOI: 15.10.3892/ol.2016.5441
16. Izadi-Mood N., Asadi K., Shojaei H. et al. Potential diagnostic value of P16 expression in premalignant and malignant cervical lesions. J Res Med Sci, 2012, vol. 17 (5), pp. 428–433.
17. Li Y., Liu J., Gong L. et al. Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1-2 lesions. Virol J, 2019, vol.16, p. 117. DOI: 10.1186/s12985-019-1225-6